OpenAI acquires Orchestra Bio, which builds AI agents for managing drug development, and plans to integrate its tech into OpenAI life sciences suite Rosalind (Madison Mills/Axios)
Madison Mills / Axios : OpenAI acquires Orchestra Bio, which builds AI agents for managing drug development, and plans to integrate its tech into OpenAI life sciences suite Rosalind — OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.
Sources
Related
- Get hands-free personalized help on the road with Gemini OCT 20, 2026
- Anthropic's IPO prospectus: H1 2026 revenue of $16.3B, ~20% from two customers, vs. $1.1B in H1 2025, and an $80.7B net loss driven by accounting charges (Anissa Gardizy/Wall Street Journal) OCT 20, 2026
- The Programmable Data Center — Evan Conrad, SF Compute OCT 20, 2026
- Google launches TorchTPU, an open-source version of PyTorch to let AI apps run on TPUs and Google Cloud via simple configuration changes without rewriting code (Julie Bort/TechCrunch) OCT 20, 2026
- Google has joined Amazon in attacking Nvidia’s stronghold with AI app developers OCT 20, 2026